Skip to main content
NCBI home page
Epidemiology and Infection logoLink to Epidemiology and Infection
. 1991 Aug;107(1):55–61. doi: 10.1017/s0950268800048676

Rubella in the United States: toward a strategy for disease control and elimination.

K L Herrmann 1
PMCID: PMC2272031  PMID: 1879490

Full text

PDF
55

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baba K., Yabuuchi H., Okuni H., Harima R., Minekawa Y., Taniuchi M., Otsuka T., Takahashi M., Okuno Y. Rubella epidemic in an institution: protective value of live rubella vaccine and serological behavior of vaccinated, revaccinated and naturally immune groups. Biken J. 1978 Mar;21(1):25–31. [PubMed] [Google Scholar]
  2. Balfour H. H., Jr, Groth K. E., Edelman C. K., Amren D. P., Best J. M., Banatvala J. E. Rubella viraemia and antibody responses after rubella vaccination and reimmunization. Lancet. 1981 May 16;1(8229):1078–1080. doi: 10.1016/s0140-6736(81)92243-1. [DOI] [PubMed] [Google Scholar]
  3. Centers for Disease Control (CDC) Rubella and congenital rubella syndrome--United States, 1985-1988. MMWR Morb Mortal Wkly Rep. 1989 Mar 24;38(11):173–178. [PubMed] [Google Scholar]
  4. Greaves W. L., Orenstein W. A., Hinman A. R., Nersesian W. S. Clinical efficacy of rubella vaccine. Pediatr Infect Dis. 1983 Jul-Aug;2(4):284–286. doi: 10.1097/00006454-198307000-00005. [DOI] [PubMed] [Google Scholar]
  5. O'Shea S., Best J. M., Banatvala J. E. Viremia, virus excretion, and antibody responses after challenge in volunteers with low levels of antibody to rubella virus. J Infect Dis. 1983 Oct;148(4):639–647. doi: 10.1093/infdis/148.4.639. [DOI] [PubMed] [Google Scholar]
  6. Orenstein W. A., Bart K. J., Hinman A. R., Preblud S. R., Greaves W. L., Doster S. W., Stetler H. C., Sirotkin B. The opportunity and obligation to eliminate rubella from the United States. JAMA. 1984 Apr 20;251(15):1988–1994. [PubMed] [Google Scholar]
  7. Plotkin S. A., Farquhar J. D., Ogra P. L. Immunologic properties of RA27-3 rubella virus vaccine. A comparison with strains presently licensed in the United States. JAMA. 1973 Aug 6;225(6):585–590. doi: 10.1001/jama.225.6.585. [DOI] [PubMed] [Google Scholar]
  8. Preblud S. R. Some current issues relating to rubella vaccine. JAMA. 1985 Jul 12;254(2):253–256. [PubMed] [Google Scholar]
  9. Schaffner W., Fleet W. F., Kilroy A. W., Lefkowitz L. B., Herrmann K. L., Thompson J., Karzon D. T. Polyneuropathy following rubella immunization. A follow-up study and review of the problem. Am J Dis Child. 1974 May;127(5):684–688. doi: 10.1001/archpedi.1974.02110240070008. [DOI] [PubMed] [Google Scholar]
  10. Tingle A. J., Allen M., Petty R. E., Kettyls G. D., Chantler J. K. Rubella-associated arthritis. I. Comparative study of joint manifestations associated with natural rubella infection and RA 27/3 rubella immunisation. Ann Rheum Dis. 1986 Feb;45(2):110–114. doi: 10.1136/ard.45.2.110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Tingle A. J., Yang T., Allen M., Kettyls G. D., Larke R. P., Schulzer M. Prospective immunological assessment of arthritis induced by rubella vaccine. Infect Immun. 1983 Apr;40(1):22–28. doi: 10.1128/iai.40.1.22-28.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Epidemiology and Infection are provided here courtesy of Cambridge University Press

RESOURCES